Apollo Hospitals is basically India’s most premium medical mall – you enter with a headache, and exit with a bill that can also cause one. Q1 FY26 delivered ₹5,842 Cr sales (+14.9% YoY) and ₹433 Cr profit (+41.8% YoY). Sounds healthy? Yes, until you see the debt swelling to ₹7,864 Cr – like a patient eating samosas right after a bypass.
2. Introduction
Since 1983, Apollo has been performing CPR on India’s healthcare sector – and billing us for it. Dr. Prathap C Reddy’s masterstroke was realizing early that middle-class Indians wanted hospitals that didn’t look like government railway stations. The model worked – private corporate healthcare became a thing, and Apollo became the Baba Ramdev of beds.
Today, it’s not just hospitals – it’s pharmacies, diagnostic labs, health-tech apps, dialysis centers, robotic surgery, and even a side hustle in insurance. Basically, Apollo has turned into an entire healthcare SaaS company with beds attached.
But behind the glossy headlines, Apollo’s balance sheet has started resembling a patient chart – vitals okay, but rising pressure in the borrowings section. They’re on an expansion spree (adding 3,500+ beds with ₹4,400 Cr capex) and also pulling off a complicated merger of Apollo HealthCo + Keimed to create a ₹25,000 Cr omni-channel pharmacy beast.
So, is Apollo a doctor of wealth or a patient on IV drip? Let’s dissect.
3. Business Model – WTF Do They Even Do?
Apollo’s business is a buffet – you pick your poison:
Hospitals (52%) – 73 hospitals, 10,134 beds. Average Room Price of Bed (ARPOB) at ₹59,053. Even the Taj Mahal’s entry ticket is cheaper.
Pharmacy & Digital (41%) – 6,228 stores, Apollo 24×7 app with 36M users. It’s basically the Swiggy for Crocin. Daily active users: 7.7 lakh – clearly India is popping pills faster than ordering pizzas.
Diagnostics & Retail Health (7%) – 2,200 diagnostic centers, 133 dialysis centers, 183 dental centers. They’re making money from every possible body hole – nose swabs, urine tests, dental crowns, you name it.
Throw in robotic surgeries (17,000 completed) and transplants, and Apollo has a side hustle in everything from liver to love handles.
Commentary: Even hospitals need oxygen when the P/E is 65x. You could say investors are paying for Apollo’s “bed capacity” like Delhiites pay for VIP darshan.
5. Valuation Discussion – Fair Value Range
Method 1: P/E Industry average ~60x. Apollo at ~65x. Annualised EPS ~₹120. Fair Value Range = ₹7,200 – ₹8,000.
Method 2: EV/EBITDA EV = ₹1,19,735 Cr; EBITDA (TTM) = ₹3,199 Cr. EV/EBITDA = 37x. Healthcare peers at ~30–35x. Fair Range = ₹6,800 – ₹7,800.
